# Telomeres

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Mechanism
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/telomere-science.html

> Telomeres are the protective caps on chromosome ends that shorten with each cell division, and their length is one of the more reliable biological aging markers. Elongation was long considered one-directional in adults, but a 2025 RCT showed the SGLT2 inhibitor henagliflozin lengthened leukocyte telomeres in 26 weeks, a 2026 RCT showed combined physical and cognitive training lengthened them in MCI patients, and hTERT mRNA therapy produced sustained elongation in telomere-disorder patients. Whether lengthening telomeres slows human aging is unproven, and the cancer question remains open.

> Telomeres — the protective caps on chromosome ends — shorten with each cell division. When they become critically short, cells enter replicative senescence. Telomere length is one of the most reliable biological aging markers. Telomerase, the enzyme that lengthens telomeres, can be activated pharmacologically and with peptide bioregulators like [Epitalon](epitalon-aedg-tetrapeptide-telomerase-pineal-axis-and-geroprotective-evidence.html).

## Telomere Biology

### What Are Telomeres?

  * **Repetitive DNA sequences** (TTAGGG in humans) at chromosome ends
  * **Function:** Protect chromosome ends from degradation and fusion
  * **The "end replication problem":** DNA polymerase cannot fully replicate the 3' end → telomeres shorten with each cell division
  * **Hayflick limit:** Normal human cells divide ~50-70 times before senescence (largely telomere-driven)



### Telomere Length Across Lifespan

  * **Newborn:** ~10,000 base pairs
  * **Adult:** ~5,000-8,000 base pairs
  * **Senescence threshold:** ~3,000-5,000 base pairs
  * **Rate of shortening:** ~25-50 base pairs/year (varies by tissue and lifestyle)



### Factors That Accelerate Telomere Shortening

Factor | Mechanism  
---|---  
**Chronic stress** | Cortisol → oxidative damage, reduced telomerase  
**Smoking** | Oxidative damage, inflammation  
**Obesity/insulin resistance** | [Hyperinsulinemia](metabolic-health-and-insulin.html) → inflammation  
**Poor sleep** | Reduced telomerase, oxidative stress  
**Sedentary lifestyle** | Reduced telomerase activity  
**Environmental toxins** | Direct DNA damage  
  
### Factors That Protect Telomeres

  * **Exercise:** Increased telomerase activity in immune cells
  * **Meditation/stress reduction:** Increased telomerase (Elizabeth Blackburn's research)
  * **[Fasting](fasting-approaches.html):** May reduce telomere attrition rate
  * **Omega-3 fatty acids:** Reduced telomere shortening in RCTs
  * **Vitamin D:** Associated with longer telomeres



## Telomerase

### The Enzyme

  * **TERT (telomerase reverse transcriptase):** Catalytic subunit — the rate-limiting component
  * **TERC (telomerase RNA component):** Template for telomere addition
  * **Activity:** Adds ~50-60 base pairs per cycle
  * **Normal expression:** Active in germ cells, stem cells, and ~85% of cancers
  * **Normal somatic cells:** TERT is repressed → progressive shortening



### Telomerase Activation Strategies

#### Pharmacological

Agent | Status | Evidence  
---|---|---  
**TA-65** (cyclostragolol) | Commercial supplement | Moderate — some evidence of telomere lengthening in humans  
**GRN510 (Telomerase activator)** | Research/Geron Corp. | Preclinical  
**Danazol** | FDA-approved (other uses) | Shown to lengthen telomeres in telomere biology disorder patients  
  
#### Peptide Bioregulators

  * **[Epitalon](epitalon-aedg-tetrapeptide-telomerase-pineal-axis-and-geroprotective-evidence.html) (Epithalamin):** Tetrapeptide developed by [Prof. Khavinson](peptide-bioregulation-khavinson.html)
  * PMID [12937682](https://pubmed.ncbi.nlm.nih.gov/12937682/) — Induces telomerase activity and telomere elongation in human somatic cells
  * PMID [40908429](https://pubmed.ncbi.nlm.nih.gov/40908429/) (2025) — Confirms telomere length increase in human cell lines
  * **Mechanism:** Upregulates TERT gene expression
  * **Uniqueness:** Activates telomerase in normal cells but NOT preferentially in cancer cells (safety advantage)



## The Cancer Question

  * **Concern:** Telomerase activation could promote cancer (since 85% of cancers reactivate telomerase)
  * **Counter-argument:** Short telomeres CAUSE genomic instability (a cancer risk factor). Telomere maintenance may actually be cancer-protective.
  * **Epitalon data:** Does not preferentially activate telomerase in cancer cell lines (PMID: [PMC12411320](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/))
  * **Honest assessment:** The cancer risk is theoretical and not observed in animal studies, but long-term human data is limited



## Breakthrough: SGLT2 Inhibitors Elongate Telomeres in Humans (2025)

> **First randomized, placebo-controlled human study to show a metabolic drug can lengthen telomeres.**

**Zhang et al. (2025). "Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes."_Cell Reports Medicine_. [PMC12490245](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490245/).**

  * **Design:** Multicenter, randomized, double-blind, placebo-controlled trial
  * **Intervention:** Henagliflozin (SGLT2 inhibitor) 10 mg/day vs. placebo for **26 weeks**
  * **Primary outcome:** Change in leukocyte telomere length
  * **Key results:**
  * **90.48% of henagliflozin patients showed telomere lengthening** vs. 65.57% placebo
  * Mean telomere length increase: 0.06 (95% CI 0.02–0.11), p = 0.011
  * Also increased PGC-1α (mitochondrial biogenesis regulator)
  * **Why this matters:**
  * Telomere length was previously considered essentially unidirectional in adults — only shortening, never lengthening
  * This trial demonstrates pharmacological telomere elongation is achievable in humans within just 6 months
  * SGLT2 inhibitors activate AMPK and SIRT1, promote senescent cell clearance, and reduce inflammation — multiple pathways converge on telomere maintenance
  * Other SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin) likely share this effect based on class mechanism



### SGLT2i Telomere Mechanism

Pathway | Effect  
---|---  
**AMPK activation** | Reduces oxidative stress, supports DNA repair  
**SIRT1 upregulation** | Promotes telomere-protective chromatin state  
**Senescent cell clearance** | Removes cells with critically short telomeres  
**Reduced systemic inflammation** | Lowers inflammatory cytokines that accelerate shortening  
**PGC-1α increase** | Enhanced mitochondrial function reduces ROS-mediated telomere damage  
  
### Implications for Telomere Science

  * Challenges the dogma that adult telomere dynamics are unidirectional (only shortening)
  * Suggests metabolic health is more tightly linked to telomere maintenance than previously appreciated
  * Positions SGLT2 inhibitors as potential telomere-protective agents beyond diabetes



## Breakthrough: hTERT Gene Therapy (EXG-34217) — First Sustained Telomere Elongation in Humans (Feb 2025)

> **First successful clinical demonstration that pharmacological delivery of hTERT can produce sustained telomere elongation in patients with telomere biology disorders (TBDs). Published in _NEJM Evidence_ 25 Feb 2025.**

**Myers K et al. (2025). "EXG-34217 for the Treatment of Telomere Biology Disorders."_NEJM Evidence_. DOI [10.1056/EVIDoa2400252](https://doi.org/10.1056/EVIDoa2400252)**

  * **Sponsor:** Elixirgen Therapeutics (Baltimore), with Kasiani Myers MD (Cincinnati Children's) as principal investigator
  * **Mechanism:** EXG-34217 is a modified mRNA-based hTERT gene-therapy platform delivering transient telomerase expression to hematopoietic stem cells
  * **Trial design:** Phase 1/2 open-label in adults and pediatric TBD patients (dyskeratosis congenita, idiopathic pulmonary fibrosis, etc.) — TBD prevalence ~1 in 1 million
  * **Key results (first two patients reported):**
  * **Sustained telomere elongation** in blood cells over 24-month and 5-month follow-up windows, respectively
  * **No treatment-related safety concerns** observed in either patient to date
  * Telomere elongation exceeded the threshold historically considered the natural variability band for qPCR-based LTL measurement
  * **Why this matters:**
  * Telomere biology disorders (TBDs) — dyskeratosis congenita, Coats plus, Hoyeraal-Hreidersson syndrome — cause bone marrow failure, pulmonary fibrosis, and premature aging through inherited ultrac-short telomeres. Prior treatment options (androgens, danazol) had limited efficacy and side effects.
  * Successful telomere elongation in TBD patients validates hTERT delivery as a clinical modality
  * Findings are NOT directly transferable to healthy adults (oncology risk, dosing, target cells differ) but provide proof-of-concept for the platform



**Acquisition context:** OrganaBio acquired Elixirgen Therapeutics May 2026 (Drug Discovery News, May 2026). The hTERT-mRNA platform remains under clinical development for TBDs.

**Mouse-model corroboration:** Bernardes de Jesus B et al. (2012/updated 2026) showed AAV9-Tert gene therapy ameliorates neurodegeneration associated with short telomeres in mice (Aging-US 2026 update of the original 2012 _EMBO Molecular Medicine_ paper).

## Exercise & Combined Training Lengthen Telomeres — Train the Brain RCT (2026)

**Borghini A et al. (2026). "Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients."_BMC Geriatrics_. DOI [10.1186/s12877-026-07380-3](https://doi.org/10.1186/s12877-026-07380-3)**

  * **Design:** Randomized controlled trial ("Train the Brain"), n=94 MCI patients (75.1 ± 5.1 years) + 37 non-MCI controls (73.2 ± 4.6 years); MCI arm randomized to **7 months of combined physical + cognitive training** vs. standard care
  * **Key outcomes:
  * MCI patients had shorter baseline LTL than non-MCI controls (p = 0.02)
  * Short LTL → ORadjusted = 2.6 (95% CI 1.1–6.0) for MCI risk
  * Training improved ADAS-cog scores (T0 = 15.1 ± 4.8 → T7 = 13.4 ± 5.0, p = 0.01)
  * Training **increased LTL** (T0 = 0.97 ± 0.21 → T7 = 1.04 ± 0.23, p = 0.04) — first RCT to demonstrate non-pharmacological telomere elongation in MCI
  * **Mechanistic biomarker findings (n=24 subset):**
  * **hTERT mRNA negligible** at T0 and T7 in MCI patients — elongation is NOT via increased telomerase activity
  * **TERRA (telomeric repeat-containing RNA)** increased in untrained MCI (p = 0.02), suggesting impaired telomere homeostasis → telomeric non-coding RNA now a therapeutic target for age-related disease
  * **Implication:** The telomere-elongation signal in exercise trials is real but the mechanism may be **redox/metabolic substrate preservation** , not direct telomerase induction. Matches the framing of Lee KH et al. (2026) review.



**Lee KH, Song KJ, Shin YA (2026). "Reframing Telomere Biology in Exercise Science: From Descriptive Metrics to Redox–Metabolic Mechanisms for Precision Healthy Aging (2000–2025)."_Biomedicines_ 14(6):1396. DOI [10.3390/biomedicines14061396](https://doi.org/10.3390/biomedicines14061396). [PMC13297515](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13297515/).** — Comprehensive 2025 narrative review concluding that exercise-induced telomere changes are mediated primarily through redox-metabolic pathways (mitochondrial ROS, NAD+/SIRT1, antioxidant enzymes) rather than through telomerase upregulation per se.

## Testing Telomere Length

Method | What It Measures | Utility  
---|---|---  
**qPCR (relative TL)** | Average telomere length | Most commercial tests use this  
**Flow-FISH** | Cell-by-cell telomere length | More precise  
**TRF (terminal restriction fragment)** | Gold standard research method | Most accurate but expensive  
**HT-Q-FISH** | High-throughput single-cell | Research  
**Commercial tests** (TeloYears, etc.) | Relative length | Useful for tracking trends

## Sources

1. Khavinson VKh et al. (2003). "Epithalon Peptide Induces Telomerase Activity." PMID 12937682 (PubMed 12937682)
2. PubMed 40908429 (PubMed 40908429)
3. Epitalon Telomere Study (2025). PMC12411320 (PMC12411320)
4. Zhang et al. (2025). "Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes." Cell Reports Medicine . PMC12490245 . — First RCT showing pharmacological telomere elongation in humans (PMC12490245)
5. Myers K et al. (2025). "EXG-34217 for the Treatment of Telomere Biology Disorders." NEJM Evidence . DOI 10.1056/EVIDoa2400252 . — First clinical trial of hTERT mRNA gene therapy showing sustained telomere elongation in TBD patients (DOI 10.1056/EVIDoa2400252)
6. Borghini A et al. (2026). "Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients." BMC Geriatrics . DOI 10.1186/s12877-026-07380-3 . — Train the Brain RCT — first RCT to show non-pharmacological LTL increase in MCI (DOI 10.1186/s12877-026-07380-3)
7. Lee KH, Song KJ, Shin YA (2026). "Reframing Telomere Biology in Exercise Science: From Descriptive Metrics to Redox–Metabolic Mechanisms for Precision Healthy Aging (2000–2025)." Biomedicines 14(6):1396. DOI 10.3390/biomedicines14061396 . PMC13297515 . (DOI 10.3390/biomedicines14061396, PMC13297515)
8. Yesilyurt-Dirican ZE et al. (2025). "SGLT2 inhibitors as a novel senotherapeutic approach." npj Aging . 11(1):35. DOI 10.1038/s41514-025-00227-y (DOI 10.1038/s41514-025-00227-y)